Mechanisms and Treatment of Exercise Intolerance and Persistent Fatigue in Spinal Muscular Atrophy

Columbia University

Status

Enrolling

Conditions

Spinal Muscular Atrophy

Treatments

Other: Observational

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT05518773

AAAT5811

Details and patient eligibility

About

This study will focus on the pathophysiological underpinnings of reduced exercise capacity and fatigue in ambulatory patients with spinal muscular atrophy (SMA). There has been laboratory evidence to suggest that the molecular mechanisms underlying mitochondrial biogenesis may be vulnerable to survival motor neuron (SMN) protein deficiency. This is an observational, single visit study including 34 ambulatory SMA patients treated with SMN repletion therapies (risdiplam or nusinersen) for at least 6 months at enrollment.

Full description

SMN depletion affects muscle mitochondria and thus muscle function as a result. The relationship between these and their effect(s) on fatigue in the context of SMN repletion treatment has not been evaluated. If muscle function is vulnerable to SMN insufficiency, treatment strategies targeting muscle in addition to the central nervous system (motor neurons) may ameliorate fatigue and improve exercise capacity, thereby improving quality of life and bringing SMA treatments closer to a cure. This project explores such an idea by comparing the effects of the two different SMN repletion modalities in patients. This is an observational cross-sectional study involving ambulatory SMA children and adults treated for at least 6 months with SMN repletion therapy, either (1) systemically with risdiplam, or (2) intrathecally (central nervous system-only), with nusinersen.

Enrollment

34 estimated patients

Sex

All

Ages

8 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Genetic confirmation of SMA with laboratory documentation of homozygous deletion of survival motor neuron (SMN1) exon 7;
At least 8 years of age at time of signing Informed Consent Form (or assent)
Children or adults currently receiving treatment, for at least 6 months, with SMN repletion therapy, either with

(1) risdiplam, or (2) nusinersen
Able to walk independently at least 25 meters
Able to tread a stationary cycle ergometer.

Exclusion criteria

Unable to walk 25 meters independently.
Use of investigational medications intended for the treatment of SMA within 30 days prior to study entry.
The presence of any contraindication to exercise according the American College of Sports Medicine (ACSM) criteria.